BELITE BIO INC - AMERICAN DEPOSITARY SHARES

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

19 Jul 2022 16:05:33 By Nasdaq GlobeNewswire

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

12 May 2022 16:30:00 By Nasdaq GlobeNewswire

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

05 May 2022 08:00:02 By Nasdaq GlobeNewswire

Belite Bio Announces Closing of $36 Million Initial Public Offering

03 May 2022 16:30:00 By Nasdaq GlobeNewswire

Belite Bio Receives FDA Fast Track Designation For LBS-008

03 May 2022 06:50:00 By Nasdaq GlobeNewswire